Organization
University of Milan-Bicocca and Gynecologic Oncology Program
1 abstract
Abstract
A phase IV trial to confirm the efficacy of olaparib in combination with bevacizumab as maintenance frontline treatment of HRD-positive ovarian tumours (IOlanTHe).Org: Humanitas University + IRCCS Humanitas Research Hospital, Unit of Gynaecological Oncology Research, University of Milan-Bicocca and Gynecologic Oncology Program, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Obstetrics and Gynecology Unit ASO Ordine Mauriziano,